MSMartin Schaefer

Martin Schaefer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Martin Schaefer has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Andreas Heinz

    Department of Psychiatry and Psychotherapy, Technische Universität Dresden, Dresden, Germany

    7 shared publications
  • Axel Hinzpeter

    Charité—Universitätsmedizin Berlin, Klinik und Poliklinik für Psychiatrie und Psychotherapie—Campus Charité Mitte, Berlin, Germany

    3 shared publications
  • Markus Schwaiger

    Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

    3 shared publications
  • Astrid Friebe

    2 shared publications
  • Folkhard Schmidt

    Department of Psychiatry, Ludwig-Maximilians-University, Nussbaumstr. 7, D-80336 Munich, Germany

    2 shared publications
  • Maurice Pich

    Charité—Universitätsmedizin Berlin, Klinik und Poliklinik für Psychiatrie und Psychotherapie—Campus Charité Mitte, Berlin, Germany

    2 shared publications

Latest Publications

  • Three Cases of Successful Tryptophan Add-On or Monotherapy of Hepatitis C and IFNα-Associated Mood Disorders

    by Martin Schaefer, Jochen Winterer, Rahul Sarkar, Ralf Uebelhack, Leonora Franke, Andreas Heinz, Astrid Friebe


  • Open Access

    Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin

    by Martin Schaefer, Axel Hinzpeter, Ariane Mohmand, Gesa Janssen, Maurice Pich, Markus Schwaiger, Rahul Sarkar, Astrid Friebe, Andreas Heinz, Michael Kluschke, et al.

    We investigated and compared the results of treating the chronic hepatitis C (HCV) infection of different groups of psychiatric-risk patients and controls with pegylated interferon alpha (pegIFN-α) plus ribavirin. Seventy patients were prospectively screened for psychiatric disorders. Seventeen patients without psychiatric diseases or drug addiction (controls), 22 patients with psychiatric disorders, 18 patients who had received methadone substitution treatment and 13 patients who were former drug users were treated with pegIFN-α plus ribavirin. Sustained virological response (SVR), adherence, and psychiatric side effects (using the Montgomery-Asberg Depression Rating Scale and the Brief Psychiatric Rating Scale) in the groups were compared. An SVR was found in 58.6% of all patients: 58.8% of the controls, 50% of psychiatric patients, 72.2% of methadone patients, and 53.8% of former drug users. Methadone-substituted patients and former drug users had significantly higher dropout rates. Scores for neither depressive nor psychotic symptoms differed significantly between groups during treatment. However, the controls had lower pretreatment scores, followed by a significant higher increase to maximum scores. A stepwise logistic regression model showed that only genotype, not group (control, psychiatric, methadone, or former drug abuse), type of psychiatric diagnosis (affective disorder, personality disorder, or schizophrenic disorder), depression scores before and during treatment, change in depression score, antidepressive treatment, sex, or liver enzymes before treatment, was associated with SVR. Conclusion: In an interdisciplinary treatment setting psychiatric diseases and/or drug addiction did not negatively influence psychiatric tolerability of and antiviral response rate to HCV treatment with pegIFN-α and ribavirin. (HEPATOLOGY 2007.)


  • Memantine-associated Reversal of Clozapine-induced Weight Gain

    by M. Schaefer, K. Leopold, A. Hinzpeter, A. Heinz, M. Krebs

    Introduction: Weight gain is a frequently observed adverse event in the treatment with atypical antipsychotics that significantly affects the patients’ physical health and treatment compliance. Methods: We report on a treatment-resistant schizophrenic patient who received an add-on treatment with the low-affinity NMDA antagonist memantine because of cognitive disturbances. Results: During this treatment we observed a marked decrease of clozapine-induced weight gain. The causal relationship to memantine could be demonstrated using an on-off-on design with a significant increase of weight after discontinuation and again a substantial weight loss after re-exposition with memantine. Beside weight, also negative symptoms improved. Discussion: Prospective controlled trials evaluating the safety and possible positive effects of memantine on antipsychotic induced weight gain are needed.


  • Levetiracetam for the Treatment of Alcohol Withdrawal Syndrome

    by Michael Krebs, Karolina Leopold, Christoph Richter, Thorsten Kienast, Axel Hinzpeter, Andreas Heinz, Martin Schaefer


  • Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C

    by Martin Schaefer, Markus Schwaiger, Andrea S. Garkisch, Maurice Pich, Axel Hinzpeter, Ralf Uebelhack, Andreas Heinz, Florian van Boemmel, Thomas Berg


  • Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-α

    by Martin Schaefer, Martin Horn, Folkhard Schmidt, Monika H. Schmid-Wendtner, Matthias Volkenandt, Manfred Ackenheil, Norbert Mueller, Markus J. Schwarz


  • Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?

    by Martin Schaefer, Andreas Heinz, Markus Backmund

    Aims Approximately 170 million people world‐wide are chronically infected with the hepatitis C virus (HCV). While the seroprevalence in the general population ranges between 0.2 and 2%, 50–90% of injection drug users are chronically HCV‐infected. However, most patients who are drug abusers are still excluded from treatment of chronic HCV infection with interferon (IFN)‐α. Due to the recent treatment advances resulting in sustained response rates between 50 and 80%, it becomes increasingly important to reflect the still existing contraindications and restrictions for IFN‐α treatment, especially for patients with intravenous drug use (IDU) with or without psychiatric comorbidity.Methods We reviewed clinical trials that focus on the treatment of chronic hepatitis C in patients with drug addiction published between 1987 and 2003.Findings Only seven clinical trials investigating HCV treatment among drug users were found: four open prospective uncontrolled trials and three controlled trials. Thus far, no trials using pegylated IFN‐α have been conducted. Data about sustained response and adherence in HCV‐infected methadone substituted patients were either comparable to control groups or to representative clinically controlled trials using the same treatment regimen (IFN‐α monotherapy or combined with ribavirin). Patients with former or present drug abuse seem more likely to discontinue treatment early. HCV‐infected IDUs tended to be older with higher inflammatory activity and stage of fibrosis when interferon treatment was started. Psychiatric comorbidity did not negatively influence adherence or treatment outcome.Conclusions There is no clinical evidence suggesting that HCV treatment with IFN‐α should be limited to IDUs or methadone substituted patients. However, more prospective controlled trials on HCV treatment for patients with IDU are needed to establish and apply new rules and guidelines.


  • Neurotransmitter Changes by Interferon-Alpha and Therapeutic Implications

    by M Schaefer, M Schwaiger, M Pich, K Lieb, A Heinz

    Interferon alpha (IFN-α) is a cytokine that is widely used for the treatment of chronic viral infection or malignant disorders. During treatment with IFN-α, severe neuropsychiatric syndromes may occur such as depression with suicidal ideation, paranoid psychoses or confusional states. The neurobiological correlates of these side effects are widely unknown. Besides induction of other cytokines and hormonal changes, IFN-α has been shown to modulate the opioid, serotonin, dopamine and glutamate neurotransmitter system. Positive therapeutic effects of antidepressants such as selective serotonin-reuptake-inhibitors (SSRI) or of opioid receptor antagonists support the hypothesis that neurotransmitter changes play an important role in the development of IFN-α associated neuropsychiatric side effects. We review recent research about IFN-associated neurotransmitter changes in the central nervous system and discuss treatment strategies.


  • Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

    by Martin Schaefer, Folkhard Schmidt, Christian Folwaczny, Reinhard Lorenz, Gaby Martin, Norbert Schindlbeck, Walter Heldwein, Michael Soyka, Heinz Grunze, August Koenig, et al.

    Psychiatric disorders or drug addiction are often regarded as contraindications against the use of interferon alfa (IFN-α) in patients with chronic hepatitis C. Our aim was to obtain prospective data on adherence to as well as efficacy and mental side effects of treatment with IFN-α in different psychiatric risk groups compared with controls. In a prospective trial, 81 patients with chronic hepatitis C (positive hepatitis C virus[HCV] RNA and elevated alanine aminotransferase[ALT] level) and psychiatric disorders (n = 16), methadone substitution (n = 21), former drug addiction (n = 21), or controls without a psychiatric history or drug addiction (n = 23) were treated with a combination of IFN-α-2a 3 MU 3 times weekly and ribavirin (1,000-1,200 mg/d). Sustained virologic response (overall, 37%) did not differ significantly between subgroups. No significant differences between groups were detected with respect to IFN-α-related development of depressions during treatment. However, in the psychiatric group, significantly more patients received antidepressants before and during treatment with IFN-α (P < .001). Most of those who dropped out of the study were patients with former drug addiction (43%; P = .04) compared with 14% in the methadone group, 13% in the control group, and 18% in the psychiatric group. No patient in the psychiatric group had to discontinue treatment because of psychiatric deterioration. In conclusion, our data do not confirm the supposed increased risk for IFN-α-induced mental side effects and dropouts in psychiatric patients if interdisciplinary care and antidepressant treatment are available. Preexisting psychiatric disorders or present methadone substitution should no longer be regarded as contraindications to treatment of chronic hepatitis C with IFN-α and ribavirin in an interdisciplinary setting.